Payers in the US do not embrace a single, dominant method for determining the value of new technologies. With this mind, Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value framework” to guide the assessment of drugs and devices in the US. At this OHE Lunchtime Seminar, he will present this framework and seek input on its method for integrating elements of cost-effectiveness and affordability.
Payers in the US do not embrace a single, dominant method for determining the value of new technologies. With this mind, Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients' groups, and clinician specialty societies to help develop a “value framework” to guide the assessment of drugs and devices in the US. At this OHE Lunchtime Seminar, he will present this framework and seek input on its method for integrating elements of cost-effectiveness and affordability.
Dr Pearson is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit health technology assessment organization based in Boston, Massachusetts. ICER’s programs include the California Technology Assessment Forum and the New England Comparative Effectiveness Public Advisory Council, both of which seek to support all health care decision makers in the interpretation and application of evidence on clinical effectiveness and value. Dr Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and has served as Special Advisor, Technology and Coverage Policy, within the Coverage and Analysis Group at the US Centers for Medicare and Medicaid Services. He has also been a Senior Visiting Fellow at England’s National Institute for Health and Care Excellence (NICE), the Vice Chair of the US Medicare Evidence Development and Coverage Advisory Committee (MedCAC), and a Senior Fellow at America’s Health Insurance Plans (AHIP).
